BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 11316217)

  • 1. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
    Morris CD; Armstrong GR; Bigley G; Green H; Attwood SE
    Am J Gastroenterol; 2001 Apr; 96(4):990-6. PubMed ID: 11316217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of COX-2 expression with corresponding active and chronic inflammatory reactions in Barrett's metaplasia and progression to cancer.
    Ling FC; Baldus SE; Khochfar J; Xi H; Neiss S; Brabender J; Metzger R; Drebber U; Dienes HP; Bollschweiler E; Hoelscher AH; Schneider PM
    Histopathology; 2007 Jan; 50(2):203-9. PubMed ID: 17222248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas.
    Wilson KT; Fu S; Ramanujam KS; Meltzer SJ
    Cancer Res; 1998 Jul; 58(14):2929-34. PubMed ID: 9679948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells.
    Souza RF; Shewmake K; Beer DG; Cryer B; Spechler SJ
    Cancer Res; 2000 Oct; 60(20):5767-72. PubMed ID: 11059772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.
    Abdalla SI; Lao-Sirieix P; Novelli MR; Lovat LB; Sanderson IR; Fitzgerald RC
    Clin Cancer Res; 2004 Jul; 10(14):4784-92. PubMed ID: 15269153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
    Dorer R; Odze RD
    Am J Surg Pathol; 2006 Jul; 30(7):871-7. PubMed ID: 16819330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
    O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
    Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma.
    Morales CP; Lee EL; Shay JW
    Cancer; 1998 Aug; 83(4):652-9. PubMed ID: 9708927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus.
    Glickman JN; Blount PL; Sanchez CA; Cowan DS; Wongsurawat VJ; Reid BJ; Odze RD
    Hum Pathol; 2006 Oct; 37(10):1304-15. PubMed ID: 16949933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis.
    Ishimura N; Amano Y; Sanchez-Siles AA; Fukuhara H; Takahashi Y; Uno G; Tamagawa Y; Mishima Y; Yuki T; Ishihara S; Kinoshita Y
    J Clin Gastroenterol; 2011 Sep; 45(8):665-72. PubMed ID: 21325951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barrett's oesophagus with predominant intestinal metaplasia correlates with superficial cyclo-oxygenase-2 expression, increased proliferation and reduced apoptosis: changes that are partially reversed by non-steroidal anti-inflammatory drugs usage.
    Amano Y; Ishihara S; Kushiyama Y; Yuki T; Takahashi Y; Chinuki D; Miyake T; Miyaoka Y; Rumi MA; Ishimura N; Adachi K; Kinoshita Y
    Aliment Pharmacol Ther; 2004 Oct; 20(7):793-802. PubMed ID: 15379840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus.
    Srivastava A; Hornick JL; Li X; Blount PL; Sanchez CA; Cowan DS; Ayub K; Maley CC; Reid BJ; Odze RD
    Am J Gastroenterol; 2007 Mar; 102(3):483-93; quiz 694. PubMed ID: 17338734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study.
    Beales IL; Ogunwobi O; Cameron E; El-Amin K; Mutungi G; Wilkinson M
    BMC Cancer; 2007 Jun; 7():97. PubMed ID: 17559672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression.
    Skacel M; Petras RE; Gramlich TL; Sigel JE; Richter JE; Goldblum JR
    Am J Gastroenterol; 2000 Dec; 95(12):3383-7. PubMed ID: 11151865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma.
    Lagorce C; Paraf F; Vidaud D; Couvelard A; Wendum D; Martin A; Fléjou JF
    Histopathology; 2003 May; 42(5):457-65. PubMed ID: 12713622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
    Chatelain D; Fléjou JF
    Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA abnormalities as marker of risk for progression of Barrett's esophagus to adenocarcinoma: image cytometric DNA analysis in formalin-fixed tissues.
    Fang M; Lew E; Klein M; Sebo T; Su Y; Goyal R
    Am J Gastroenterol; 2004 Oct; 99(10):1887-94. PubMed ID: 15447746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.
    Konturek PC; Kania J; Burnat G; Hahn EG
    J Physiol Pharmacol; 2006 Dec; 57 Suppl 12():15-24. PubMed ID: 17244951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controversies in Barrett's esophagus: management of high grade dysplasia.
    Sharma P
    Semin Gastrointest Dis; 2001 Jan; 12(1):26-32. PubMed ID: 11215852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preferential up-regulation of heparanase and cyclooxygenase-2 in carcinogenesis of Barrett's oesophagus and intestinal-type gastric carcinoma.
    Sonoda R; Naomoto Y; Shirakawa Y; Fujiwara Y; Yamatsuji T; Noma K; Tanabe S; Takaoka M; Gunduz M; Tsujigiwa H; Nagatsuka H; Ohara N; Yoshino T; Takubo K; Vieth M; Tanaka N
    Histopathology; 2010 Jul; 57(1):90-100. PubMed ID: 20653782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.